JP2007510670A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510670A5
JP2007510670A5 JP2006538530A JP2006538530A JP2007510670A5 JP 2007510670 A5 JP2007510670 A5 JP 2007510670A5 JP 2006538530 A JP2006538530 A JP 2006538530A JP 2006538530 A JP2006538530 A JP 2006538530A JP 2007510670 A5 JP2007510670 A5 JP 2007510670A5
Authority
JP
Japan
Prior art keywords
cancer
disease
thalidomide
use according
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006538530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037083 external-priority patent/WO2005046593A2/en
Publication of JP2007510670A publication Critical patent/JP2007510670A/ja
Publication of JP2007510670A5 publication Critical patent/JP2007510670A5/ja
Withdrawn legal-status Critical Current

Links

JP2006538530A 2003-11-06 2004-11-04 サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物 Withdrawn JP2007510670A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51740503P 2003-11-06 2003-11-06
PCT/US2004/037083 WO2005046593A2 (en) 2003-11-06 2004-11-04 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.

Publications (2)

Publication Number Publication Date
JP2007510670A JP2007510670A (ja) 2007-04-26
JP2007510670A5 true JP2007510670A5 (https=) 2007-09-13

Family

ID=34590157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538530A Withdrawn JP2007510670A (ja) 2003-11-06 2004-11-04 サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物

Country Status (14)

Country Link
US (1) US20070208057A1 (https=)
EP (2) EP2077112A1 (https=)
JP (1) JP2007510670A (https=)
KR (1) KR20060124607A (https=)
CN (1) CN1901911A (https=)
AP (1) AP2006003637A0 (https=)
AU (1) AU2004288714A1 (https=)
BR (1) BRPI0416275A (https=)
CA (1) CA2545128C (https=)
EA (1) EA200600921A1 (https=)
IL (1) IL175427A0 (https=)
OA (1) OA13284A (https=)
WO (1) WO2005046593A2 (https=)
ZA (1) ZA200603718B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP3569245A1 (en) * 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
CA2674865A1 (en) * 2007-01-15 2008-07-24 Santen Pharmaceutical Co., Ltd. Indole derivative having i.kappa.b kinase .beta. inhibitory activity
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8445529B2 (en) * 2008-07-14 2013-05-21 Santen Pharmaceutical Co., Ltd. Indole derivative having, carbamoyl group, ureido group and substituted oxy group
EP2289554A1 (en) * 2009-07-31 2011-03-02 Dafra Pharma N.V. Compositions comprising thalidomide and artemisinin for the treatment of cancer
KR101692297B1 (ko) * 2009-10-20 2017-01-04 도오쿄 인스티튜드 오브 테크놀로지 탈리도마이드 표적 인자를 이용한 스크리닝 방법
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
US20110256236A1 (en) * 2010-04-16 2011-10-20 Erian Girgis Enhancement of the Anti-Leukemic Effect of Thalidomide
ES2664872T3 (es) * 2010-06-18 2018-04-23 Taiho Pharmaceutical Co., Ltd Moduladores PRPK-TPRKB y sus usos
WO2012031603A2 (en) * 2010-09-09 2012-03-15 Danish Medical Consults Aps Airway administration of angiogenesis inhibitors
US9200263B2 (en) 2011-12-14 2015-12-01 Taiho Pharmaceutical Co., Ltd. Recombinant PRPK-TPRKB and uses thereof
WO2013123620A1 (zh) * 2012-02-24 2013-08-29 Sun Yinghao Cul4A在前列腺癌诊断、治疗及预后中的用途
WO2014180882A2 (en) * 2013-05-07 2014-11-13 Universitat De Barcelona Treatment of brain metastasis from cancer
US20160223547A1 (en) * 2013-09-13 2016-08-04 Angels SIERRA JIMÉNLEZ Marker for predicting metastasis of breast cancer
WO2016062279A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
AU2017368248A1 (en) * 2016-11-30 2019-06-06 Intrexon Corporation Steroid administration and immunotherapy
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2020219470A1 (en) * 2019-04-22 2020-10-29 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents
MX2023008091A (es) 2021-01-08 2023-07-14 Starton Therapeutics Inc Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral.
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
RU2188819C2 (ru) * 1996-08-12 2002-09-10 Селджин Корпорейшн НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB
NZ336035A (en) * 1996-11-05 2002-03-28 Childrens Medical Center Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
EP1064277B1 (en) * 1998-03-16 2005-06-15 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
KR100672892B1 (ko) * 1999-03-18 2007-01-23 셀진 코오퍼레이션 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CA2319872C (en) * 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
MXPA02009665A (es) * 2000-03-31 2005-09-08 Celgene Corp Inhibicion de actividad de ciclooxigenasa-2.
EP1676577A1 (en) * 2000-05-15 2006-07-05 Celgene Corporation Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
WO2001087306A2 (en) * 2000-05-15 2001-11-22 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
BR0110877A (pt) * 2000-05-15 2003-03-11 Celgene Corp Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
AU2002306596B2 (en) * 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2003014315A2 (en) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.

Similar Documents

Publication Publication Date Title
JP2007510670A5 (https=)
JP2006508131A5 (https=)
CA2486141A1 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
RU2348407C2 (ru) Способы и композиции с использованием иммуномодулирующих соединений для лечения и поддержания состояния при раке и других заболеваниях
US11174256B2 (en) Imidazopyridine derivatives
CA2545128A1 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
AU2013299627B2 (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP1389203B1 (en) Analogs of thalidomide as angiogenesis inhibitors
JP2008508298A5 (https=)
ZA200409387B (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AU2011336397B2 (en) Chemokine CXCR4 receptor modulators and uses related thereto
US20210137955A1 (en) Combination therapy for cancer treatment
JP7611855B2 (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
CN113786409B (zh) 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
CN115698014B (zh) 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物
KR20070047807A (ko) 이소인돌린 화합물 및 그의 사용 방법
WO2019136244A1 (en) Heterocyclic compounds for the treatment of abnormal cellular proliferation
CN101223175A (zh) 二氮杂苯并[de]蒽-3-酮化合物及抑制PARP的方法
WO2023035223A1 (zh) 药物组合物及其用途
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
Cho et al. Design, docking, and synthesis of novel indeno [1, 2-c] isoquinolines for the development of antitumor agents as topoisomerase I inhibitors
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
WO2022083657A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN114469949A (zh) 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
HUE025111T2 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors